AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca is conducting a Phase II study titled ‘Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy.’ The study aims to evaluate the efficacy and safety of combining durvalumab and bevacizumab therapies with transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) that can be treated with locoregional therapy.
Intervention/Treatment: The study tests the combination of two drugs, Durvalumab and Bevacizumab, administered intravenously, alongside a procedure called Transarterial Radioembolization (TARE) using Yttrium-90 glass microspheres. This combination aims to improve treatment outcomes for patients with HCC.
Study Design: This is an interventional study with a single-group assignment. There is no masking involved, meaning all participants and researchers know the treatment being administered. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on February 13, 2024, and is currently recruiting. The latest update was submitted on June 24, 2025. These dates are crucial as they indicate the study’s progress and current status.
Market Implications: This study could significantly impact AstraZeneca’s stock performance by potentially expanding its oncology portfolio, especially if results show improved treatment efficacy. Positive outcomes may enhance investor sentiment and position AstraZeneca favorably against competitors in the oncology market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.